Navigation Links
Synta Oncology Candidate STA-4783 Clinical Trial Results to Be,Presented at the ASCO Annual Meeting

LEXINGTON, Mass.--(BUSINESS WIRE)--May 23, 2007 - Synta Pharmaceuticals Corp., (NASDAQ: SNTA) a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that survival and sub-population data from the Phase 2b clinical trial in metastatic melanoma of the Company's lead oncology drug candidate, STA-4783, will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois on Tuesday, June 5, 2007. In this double-blind, randomized, multi-center trial, patients treated with STA-4783 in combination with paclitaxel were compared with patients treated with paclitaxel alone. All patients had stage IV metastatic melanoma.

STA-4783 is a novel, injectable, small molecule investigational drug candidate that induces a potent oxidative stress response in cancer cells, driving programmed cell death and enhancing the activity of anti-cancer agents that act through the mitochondrial apoptosis pathway, including paclitaxel. In September 2006, Synta reported positive Phase 2b results for STA-4783 in combination with paclitaxel in a double-blind, randomized, controlled, multi-center clinical trial in patients with stage IV metastatic melanoma. In November 2006, Synta received Fast Track designation from the FDA for the development of STA-4783 in metastatic melanoma. Synta plans to initiate a pivotal Phase 3 clinical trial for STA-4783 in mid-2007 and one or more Phase 2 studies in other cancer indications later in the year.

The schedule and meeting places for the presentation, together with the abstract numbers, are listed below:

Poster Presentations

Tuesday, June 5, 2007 at 8:00 a.m. to 12:00 p.m. - Poster Presentation: 17

Abstract No. 8528

"Subgroup analysis of efficacy and safety analysis of a randomized, double-blinded controlled phase 2 study of STA-47
'"/>




Page: 1 2 3

Related medicine technology :

1. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
2. Synta Pharmaceuticals to Host Conference Call Today
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
6. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
7. MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
8. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
9. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
10. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
11. CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
Post Your Comments:
(Date:4/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/pmbmv2/global_biobanking ... Biobanking Market 2015-2019" report to their offering. ... grow at a CAGR of 7.07% over the period ... divided into two segments: Equipment and Consumables. This report ... the Global Biobanking market for the period 2015-2019. ...
(Date:4/24/2015)... , April 24, 2015 Hi-Tech Pharmaceuticals ... was not the product of reliable scientific principles ... reliable basis for allegations of adulteration. The FDA ... a false premise, or misguided hope, that Methylphenylethylamine ... studies are contradicted by multiple other studies and ...
(Date:4/24/2015)... , April 24, 2015  Blueprint Medicines ... a selective and potent inhibitor of fibroblast growth ... in models of hepatocellular carcinoma (HCC) that are ... candidate, BLU-554 induced complete tumor regression in a ... FGFR4-activating ligand at the highest dose levels. These ...
Breaking Medicine Technology:Global Biobanking Market Report 2015-2019 - Increase in Strategic Collaborations with Beckman Coulter, Tecan & Thermo Fischer Scientific Dominating 2Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 2Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 3Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 4Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 5Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 6Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 3
... score of 94.4 out of 100, Elekta,s Leksell Gamma Knife® ... top among six advanced radiation therapy systems, according to KLAS ... A Dose of New Technology . The Elekta Infinity™ ... score of 84.4, improving its score over the 2010 report. ...
... 9 , 2011  OncoSec Medical Incorporated (OTCBB: ... therapies to treat skin cancer and other solid ... and CEO, will be presenting at the 22nd ... http://photos.prnewswire.com/prnh/20110314/MM64943LOGO ) 22nd Annual ...
Cached Medicine Technology:Elekta's Leksell Gamma Knife Perfexion Earns Nearly Perfect Score in 2011 KLAS Radiation Therapy Report 2OncoSec to Present at the 22nd Annual Oppenheimer Healthcare Conference 2OncoSec to Present at the 22nd Annual Oppenheimer Healthcare Conference 3
(Date:4/26/2015)... Lauderdale, FL (PRWEB) April 26, 2015 ... 1,200 pieces of medical equipment from hospitals, surgery centers ... types of equipment will be sold including radiology, surgery, ... The live auction will take place Tuesday, April 28th ... Fort Lauderdale warehouse located at 5025 North Hiatus Rd., ...
(Date:4/26/2015)... In an article published last month ... head-neck biomechanics occurring during the use of handheld electronic devices ... determine that use of a tablet increases mechanical demand on ... - more than when the neck is in a neutral ... but pointing out the potential hazards of overuse of mobile ...
(Date:4/26/2015)... April 26, 2015 MidSouth Pain ... throughout the Southeast. MidSouth Pain Treatment Center is a ... Cordova, Southaven, Oxford and Jackson, two ambulatory surgery centers ... the Southaven and Cordova locations. , Dr. Michael ... went into medicine to help people, and when I ...
(Date:4/25/2015)... Avid Collector Andrew Hawley from Vintage Rock ... Coliseum concert posters. The concert was held on 12 ... American Tour. , According to Hawley, “The poster ... Maryland. This poster blank was used to advertise the ... uses garish lettering and colors on this boxing style ...
(Date:4/25/2015)... Jersey (PRWEB) April 25, 2015 In ... aged twelve and above needed treatment for an ... to the Substance Abuse and Mental Health Services Administration’s ... 2011). Beyond these alarming numbers are harrowing stories of ... substance abuse . David H. Kerr , ...
Breaking Medicine News(10 mins):Health News:Centurion Service Group to Auction off 1,200 Lots of Medical Equipment 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 3Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 4Health News:Growing Pains for MidSouth Pain Treatment Center 2Health News:New Book Features Powerful Stories of People Who Overcame Addiction 2Health News:New Book Features Powerful Stories of People Who Overcame Addiction 3
... News) -- People affected by epilepsy are nearly eight ... schizophrenia, and those with schizophrenia are also six times ... not schizophrenic, a new study suggests. Researchers in ... may be due to genetic, environmental or neurobiological causes. ...
... the Mining Microbial Genomes for Novel Antibiotics research theme ... a recipient of the 2011 National Institutes of Health ... from some of the nation,s most promising new scientists. ... of five years, supports young investigators who have proposed ...
... Talking with doctors about cancer and cancer treatments can feel ... often need help to understand their treatment options, and the ... making life and death decisions that may affect their survival ... Cancer treatments and tests can be serious. Patients need to ...
... DURHAM, N.C. An analysis of more than 30,000 cancer ... complication than doctors may realize, causing additional hospitalizations and driving ... by a Duke Cancer Institute researcher. The study, which ... Cancer Congress in Stockholm, found that as many as one ...
... based method of family planning developed by researchers from ... so effectively meets the needs of users that they continue ... finds that women who follow the Standard Days Method, are ... effectively. Results of the large, multi-country study of 1659 women ...
... new type of nanoparticle developed in the laboratories at the ... delivery of chemotherapy to treat cancer. Wenbin Lin, PhD, ... their finding in the Sept. 14, 2011 issue of ... laboratory studies, Lin and colleagues developed and tested a new ...
Cached Medicine News:Health News:Researchers Find Link Between Epilepsy, Schizophrenia Risk 2Health News:10 ways to make better decisions about cancer care 2Health News:10 ways to make better decisions about cancer care 3Health News:Costly blood clots more common than expected among cancer patients 2Health News:Long-term effectiveness of new family planning method shown in study 2Health News:UNC scientist proves potential of new nanoparticle design for cancer therapy 2
Reliavac® 400cc kits with siliconized PVC drain, Y-connector tube...
Reliavac 100cc evacuators offer a more constant suction profile than silicone evacuators. 100cc capacity is easy for patient to carry. Bottom emptying port reduces chance of contamination....
Used with T-tubes to collect drainage after cholecystectomy. Includes T-tube adapter and two adjustable latex rubber belts....
Used following hysterectomy procedure. Often attached to Bard bile bag....
Medicine Products: